Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-04
2005-01-04
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06838467
ABSTRACT:
This invention relates to a method of treatment and dosing regimen for treating mammalian tumors by the discontinuous administration of a farnesyl transferase inhibitor over an abbreviated one to five day dosing schedule.
REFERENCES:
patent: 5834434 (1998-11-01), Sebti et al.
patent: 5874442 (1999-02-01), Doll et al.
patent: WO 9410138 (1994-05-01), None
patent: WO 9716443 (1997-05-01), None
patent: WO 9721701 (1997-06-01), None
patent: WO 9730992 (1997-08-01), None
patent: WO 9828303 (1998-07-01), None
patent: WO 9840383 (1998-09-01), None
patent: WO 9849157 (1998-11-01), None
patent: WO 9945912 (1999-09-01), None
patent: WO 0001691 (2000-01-01), None
patent: WO 0012498 (2000-03-01), None
patent: WO 0012499 (2000-03-01), None
patent: WO 0039082 (2000-07-01), None
Parada L. F. et al. “Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene,”Nature, 1982, pp. 474-478, vol. 297, No. 5866.
Santos E. et al. “T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB-and Harvey-MSV transforming genes,”Nature, 1982, pp. 343-347, vol. 298, No. 5872.
Kohl et al., “Selective Inhibition of ras-Dependent Transformation by a Farnesyltransferase Inhibitor,”Science, 1993, pp. 1934-1937, vol. 260, No. 5116.
Henley III Raymond J.
Janssen Pharmaceutica N. V.
Kriegsman Alana G.
Lopez Gabriel
LandOfFree
Dosing regimen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dosing regimen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dosing regimen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3381543